COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
COMPASS Pathways plcNASDAQ: CMPS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $0, compared with $37K a year earlier. Trailing-twelve-month depreciation & amortization was $179K. Over 3 fiscal years it compounded at -13.2% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $44.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 216K USD
- Year-over-year change
- -7.3%
- 4-year CAGR
- +5.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 216K | -7.3% |
| FY2024 | 2024-12-31 | 233K | -3.7% |
| FY2023 | 2023-12-31 | 242K | -26.7% |
| FY2022 | 2022-12-31 | 330K | +88.6% |
| FY2021 | 2021-12-31 | 175K | — |
Depreciation & Amortization vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 depreciation & amortization of $179K is the 9th highest of the 11 companies compared; the peer median is $602.5K.
- Its year-over-year change of -14.4% is the 6th highest of 10, against a peer median of -13.8%.
- Over three fiscal years its annual growth of -13.2% compares with a peer median of +12.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $25.34M | +6.1% | +2.7% | 2.6% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Sep 2026 | $9.07M | -35.4% | +79.7% | 0.8% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +307.8% | 5.0% |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $631K | -13.8% | — | — |
| LTM Mar 2026 | $574K | -20.3% | +0.2% | — | |
| LTM Mar 2026 | $350K | +12.5% | +92.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $179K | -14.4% | -13.2% | — | |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
| LTM Jun 2026 | $2.72K | -71.9% | -13.9% | — | |
| Peer median (excluding CMPS) | $602.5K | -13.8% | +12.6% | 3.8% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.